A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

Inclusion criteria

• Body mass index (BMI) between 18.5 and 29.9 kilograms per square meter (kg/m^2) (both inclusive) at screening.
• Body weight greater than (>) 50.0 kg at screening.
• Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

• Known or suspected hypersensitivity to study interventions or related products.
• Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
• Exposure to an investigational medicinal product within 30 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
• Participant is unable to refrain from or anticipates the use of any drug known to be a moderate or strong inhibitor or inducer of uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, CYP3A4, CYP2C9, MATE1, OATP1B1/1B3, BCRP, OCT2, or P-gp, including St. John's Wort for 28 days prior to dosing and throughout the study.
• Use of any medication with unknown or unspecified content within 90 days before screening.
• Use of or intent to use prescription medicinal products or non-prescription drugs (including vitamins and herbal supplements) within 14 days prior to dosing and throughout the study, as declared by the participant, except for:
• Adequate contraceptive methods.
• Hormone replacement therapy (HRT) (for menopausal females).
• Over-the-counter topical medications known to not reach systemic circulation.
• Occasional use of acetaminophen up to 2 grams (g) (4 x 0.5 g) daily.
• Not able or not willing to adhere to study procedures, including:
• Eating the food provided in the study.
• Refraining from ingesting food or drinks that are not allowed during the study.
• Swallowing tablets.
• Abstaining from concomitant medication not allowed during the study.